A drug approved in Europe is not automatically available worldwide. Different regulatory requirements, national approval procedures and varying GMP inspections lead to global differences. The article explains the background and the role of international authorities.

Different regulatory systems worldwide

Drugs are subject to national and regional approval procedures worldwide, which have evolved historically and differ significantly in terms of structure, requirements and depth of assessment. In the European Union, approval is granted centrally by the European Medicines Agency (EMA) or nationally by the competent authorities. In the USA, on the other hand, the FDA is responsible for assessing quality, safety and efficacy.

Many countries require separate approval dossiers, even if a medicinal product has already been approved in other markets. There are differences in clinical data, stability requirements and the evaluation of manufacturing processes, for example. This regulatory fragmentation means that pharmaceutical companies have to adapt and submit their products several times - often accompanied by additional GMP inspections.

GMP inspections as a central approval criterion

Compliance with Good Manufacturing Practice: GMP is a basic requirement for the approval of medicinal products worldwide. Nevertheless, GMP inspections differ considerably in terms of scope, methodology and regulatory expectations. While some authorities carry out risk-based inspections, others rely on detailed on-site inspections of all production and quality systems.

GMP inspections play a particularly important role for active ingredient manufacturers and third country sites. Deviations in the interpretation of GMP guidelines, for example in data integrity, performance qualification or cleaning validation of equipment, can lead to a site being accepted in one country but not in another. For companies, this means increased effort in inspection preparation and global quality management.

Role of international authorities and co-operation

International initiatives such as PIC/S pursue the goal of harmonising GMP standards worldwide and strengthening mutual trust between authorities. Joint guidelines, training and the exchange of inspectors are intended to avoid multiple inspections. In practice, however, this harmonisation remains limited.

Not all countries are members of such collaborations, and even within existing agreements, foreign inspection reports are not always fully recognised. National laws, political interests or different risk assessments mean that additional inspections are required. Third-country inspections in particular show how strongly national requirements influence the global approval process.

Effects on manufacturers and market access

Different approval and inspection requirements have considerable economic and organisational consequences for pharmaceutical manufacturers. Multiple GMP inspections, parallel approval procedures and differing regulatory requirements increase costs, tie up resources and delay market entry. This can be particularly critical in the case of innovative medicinal products or bottlenecks.

Strategic regulatory planning is therefore becoming increasingly important. Companies must decide at an early stage which markets are to be prioritised and how GMP compliance is to be implemented in a globally standardised manner. Structured inspection preparation, in-depth knowledge of the requirements of the FDA, EMA and other authorities as well as continuous quality assurance are crucial for successful global approval.

Our professional pharmaceutical interpreters at GMP-inspection.com have already successfully supported numerous companies in approval procedures and GMP inspections. Many years of experience and in-depth expertise are decisive factors for a smooth and efficient process. In addition, we offer precise pharmaceutical translations for documentation, SOPs and audit reports - for maximum clarity and regulatory certainty.

 

Image: freepik, freepik.com